Our highly trained interdisciplinary team use state-of-the-art AI technologies for developing novel approaches for Hit-to-lead identification and optimisation for accelerated drug development
Our highly trained interdisciplinary team use state-of-the-art AI technologies for developing novel approaches for Hit-to-lead identification and optimisation for an accelerated drug development workflow
We have created a in-house database for rare disease multi-omics data and AI-empowered toolkit for orphan drug development and repositioning
Extremely committed team help to deliver faster and meaningful information from your multi-omics dataset
Our team of data engineers help in structuring and analysing big data to make critical decisions for your businesses
Get in touch with us for accessing our rare disease platform
Our Artificial intelligence & Machine Learning based toolkit and pipelines help in performing Drug-Development & Drug-Repurposing
Our Artificial intelligence & Machine Learning based toolkit and pipelines help in achieving most out of the data
Who we are?
Aomics GmbH is an European based deep-tech healthcare startup, headquartered in Germany. By harnessing the power of publicly available and proprietary big biological data, deep learning, AI and blockchain technologies, our core focus is to develop deep-tech solutions for Personalized medicine and Orphan Drug-Discovery.
We have been developing a personalized immuno-oncology toolkit called Onco-cure. By analyzing tumour microenvironment (TME) dataset Onco-Cure analytical dashboard is aiming at predicting patient specific immune biomarkers and allows oncologists to choose and develop the optimal targeted therapies for the patients. Mission of our proprietary Onco-Cure dashboard is to deliver most insightful approved targeted tailored therapy options to the oncologists within 48 hours.
Compounds in Pipeline
Diseases of the nervous system
Congenital malformations, deformations and chromosomal abnormalities
Endocrine, nutritional and metabolic diseases
Diseases of the circulatory system
Clinical PoC Trials
Technologies under development
Proof of Concept
Testing & Validation
Launch & Marketing
Scaling & Establishing
Here are few numbers from our databases
AI processed Scientific Literature/Articles/Patents/White papers
AI extracted and integrated compounds’ data
Pharma & Academic partners
Our AI & Blockchain based Developed models
Artificial Intelligence (AI) predicts the interactions of small-molecules with the multi-omics data for personalised target prediction and drug development
We leverage molecular AI, cheminformatic and molecular docking techniques for identifying the best molecule for an accelerated drug discovery/repositioning workflow
Hit to lead generation and further optimize physicochemical properties of the lead compounds for drug development. Find other similar orphan on-shelf drugs for an efficient drug-repurposing
Aomics GmbH is a German based company founded in 2019 and is headquartered in Frankfurt am Main, Germany. Currently with the interdisciplinary team of experienced healthcare professionals, medicinal chemist and computational biologists, Aomics GmbH is entirely focused on AI & ML-based in-silico drug target identification, drug discovery and personalized medicine solution development.
"AI/Blockchain empowered high quality drug development & drug repurposing pipelines!"
Who We Are
We are a German based company, specialized in the area of drug discovery and drug target identification. By leveraging state-of-the-art artificial intelligence, multi-omics and cheminformatic techniques, we efficiently reduce the time and cost of the drug development process to several folds.
“Make the best use of the state-of-the-art digital technologies, scientific knowledge and resources to accelerate the effective development of new diagnostic techniques and therapeutics for global health”
“To develop highly efficient and effective diagnostic and therapeutic techniques for a healthy future“
“To serve the patients who are unfortunately suffering with diseases with unmet medical needs by accelerating the development of highly efficient and effective diagnostic and therapeutic techniques“
Our key priority
“Our key priority is to ensure that everyone has access to safe, affordable, fast and efficient solutions to the healthcare problems, especially for the disease areas with huge unmet medical needs”
What We Do
Would you like to start a project with us?
Reach out on the given number or write us an email for further queries regarding project requirements